Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy

Abstract excerpt

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most commonly in EGFR-mutant non-small cell lung cancer, secondary resistance mutations on the target kinase domain emerge to diminish the binding affinity of first- and second-generation inhibitors. Other alternative resistance mechanisms include...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Colorectal Cancer Treatments and Studies
• Share to Lung Cancer Treatments and Mutations